Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 298 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... September 12, 2024 Understanding FDA Emergency Use Authorization January 21, 2021 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Load more HOT NEWS Reducing Health Care Disparities Through Cancer Clinical Trials Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition Cancer Moonshot℠ Workshop Highlights Recent Research Advances
